Sanofi-Aventis (France) Stops 14 Candidate Drugs, Profit Up 15%
Reuters -- France's Sanofi-Aventis took a knife to its pipeline, slashing 14 drugs from development including four in final trials, and posted a better-than-expected rise in quarterly net income, boosting shares.